Company Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer.
The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
| Country | United States |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 185 |
| CEO | Alan Auerbach |
Contact Details
Address: 10880 Wilshire Boulevard, Suite 2150 Los Angeles, California 90024 United States | |
| Phone | 424 248 6500 |
| Website | pumabiotechnology.com |
Stock Details
| Ticker Symbol | PBYI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001401667 |
| CUSIP Number | 74587V107 |
| ISIN Number | US74587V1070 |
| Employer ID | 77-0683487 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alan H. Auerbach | Founder, Chairman, President, Chief Executive Officer and Secretary |
| Maximo F. Nougues | Chief Financial Officer and Principal Accounting Officer |
| Douglas Hunt B.Sc., FRAPS | Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance and Law Officer |
| Jeffrey Jerome Ludwig | Chief Commercial Officer |
| Mariann Ohanesian | Senior Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SCHEDULE 13G/A | Filing |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 16, 2024 | 8-K | Current Report |
| Aug 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 15, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 144 | Filing |
| Aug 7, 2024 | 8-K | Current Report |